Skip to main content
SpringerLink
Log in

Pneumocystis jiroveci in Transplant: Recognizing Risk, Understanding Prevention, and Implementing Treatment

  • Reference work entry
  • First Online:
Emerging Transplant Infections

  • 1196 Accesses

Abstract

Pneumocystis pneumonia (PJP) is caused by Pneumocystis jiroveci and is an important infection of chronically immunocompromised patients, especially those receiving higher doses of corticosteroids and those with abnormalities in cell-mediated immunity. Until recently, the vast majority of cases were in HIV patients. This has changed with an increasing proportion occurring in non-HIV patients, including in solid organ and hematopoietic stem cell transplant recipients. The risk factors, clinical presentation, and response to therapy in such patients are different than in HIV. Patients are particularly vulnerable during the initial months after transplant and at times of intensification of immunosuppression for treatment of rejection and graft-versus-host disease (GVHD). Effective prophylaxis for 6–12 months after transplant and during time of treatment for acute rejection (or GVHD) all but eliminates the risk during those periods. PJP now tends to occur in patients not receiving effective prophylaxis during high-risk periods. Reasons include persistence of intense immune compromise beyond the typical prophylaxis periods, failure to prescribe prophylaxis, non-adherence, and occasionally breakthrough infection. Clinical manifestations tend to be more abrupt and severe than in those with HIV, and prompt treatment is imperative. Empiric therapy is often warranted, but establishing the diagnosis is important to limit unnecessary exposure to potentially toxic therapy and potentially lifetime secondary prophylaxis. Traditional tests (staining of induced sputum and bronchoalveolar lavage fluid) continue to be a mainstay of diagnosis, now complemented by nucleic acid testing of respiratory tract specimens and serum beta-D-glucan assays.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 699.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 899.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Edman JC, Kovacs JA, Masur H, Santi DV, Elwood HJ, Sogin ML. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature. 1988;334(6182):519–22.

    Article  CAS  PubMed  Google Scholar 

  2. Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med. 2004;350(24):2487–98.

    Article  CAS  PubMed  Google Scholar 

  3. Durand-Joly I, Aliouat el M, Recourt C, Guyot K, Francois N, Wauquier M, et al. Pneumocystis carinii f. sp. hominis is not infectious for SCID mice. J Clin Microbiol. 2002;40(5):1862–5.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Skalski JH, Kottom TJ, Limper AH. Pathobiology of Pneumocystis pneumonia: life cycle, cell wall and cell signal transduction. FEMS Yeast Res. 2015;15(6)

    Google Scholar 

  5. Schildgen V, Mai S, Khalfaoui S, Lusebrink J, Pieper M, Tillmann RL, et al. Pneumocystis jirovecii can be productively cultured in differentiated CuFi-8 airway cells. MBio. 2014;5(3):e01186–14.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Gigliotti F, Limper AH, Wright T. Pneumocystis. Cold Spring Harb Perspect Med. 2014;4(12):a019828.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Sokulska M, Kicia M, Wesolowska M, Hendrich AB. Pneumocystis jirovecii – from a commensal to pathogen: clinical and diagnostic review. Parasitol Res. 2015;114(10):3577–85.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Ma L, Cisse OH, Kovacs JA. A molecular window into the biology and epidemiology of Pneumocystis spp. Clin Microbiol Rev. 2018;31(3):e00009-18.

    Article  PubMed  PubMed Central  Google Scholar 

  9. McClarey A, Phelan P, O’Shea D, Henderson L, Gunson R, Laurenson I. Lessons learned from a Pneumocystis pneumonia outbreak at a Scottish renal transplant Centre. J Hosp Infect. 2019;

    Google Scholar 

  10. Medrano FJ, Montes-Cano M, Conde M, de la Horra C, Respaldiza N, Gasch A, et al. Pneumocystis jirovecii in general population. Emerg Infect Dis. 2005;11(2):245–50.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Szydlowicz M, Jakuszko K, Szymczak A, Piesiak P, Kowal A, Kopacz Z, et al. Prevalence and genotyping of Pneumocystis jirovecii in renal transplant recipients-preliminary report. Parasitol Res. 2019;118(1):181–9.

    Article  PubMed  Google Scholar 

  12. Fritzsche C, Riebold D, Fuehrer A, Mitzner A, Klammt S, Mueller-Hilke B, et al. Pneumocystis jirovecii colonization among renal transplant recipients. Nephrology (Carlton). 2013;18(5):382–7.

    Article  Google Scholar 

  13. Vestereng VH, Bishop LR, Hernandez B, Kutty G, Larsen HH, Kovacs JA. Quantitative real-time polymerase chain-reaction assay allows characterization of pneumocystis infection in immunocompetent mice. J Infect Dis. 2004;189(8):1540–4.

    Article  CAS  PubMed  Google Scholar 

  14. Kovacs JA, Masur H. Evolving health effects of Pneumocystis: one hundred years of progress in diagnosis and treatment. JAMA. 2009;301(24):2578–85.

    Article  CAS  PubMed  Google Scholar 

  15. Gajdusek DC. Pneumocystis carinii; etiologic agent of interstitial plasma cell pneumonia of premature and young infants. Pediatrics. 1957;19(4 Pt 1):543–65.

    Article  CAS  PubMed  Google Scholar 

  16. Patterson L, Coyle P, Curran T, Verlander NQ, Johnston J. Changing epidemiology of Pneumocystis pneumonia, Northern Ireland, UK and implications for prevention, 1 July 2011–31 July 2012. J Med Microbiol. 2017;66(11):1650–5.

    Article  PubMed  Google Scholar 

  17. Wickramasekaran RN, Jewell MP, Sorvillo F, Kuo T. The changing trends and profile of pneumocystosis mortality in the United States, 1999–2014. Mycoses. 2017;60(9):607–15.

    Article  PubMed  Google Scholar 

  18. Roux A, Canet E, Valade S, Gangneux-Robert F, Hamane S, Lafabrie A, et al. Pneumocystis jirovecii pneumonia in patients with or without AIDS, France. Emerg Infect Dis. 2014;20(9):1490–7.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc. 1996;71(1):5–13.

    Article  CAS  PubMed  Google Scholar 

  20. Roblot F, Le Moal G, Kauffmann-Lacroix C, Bastides F, Boutoille D, Verdon R, et al. Pneumocystis jirovecii pneumonia in HIV-negative patients: a prospective study with focus on immunosuppressive drugs and markers of immune impairment. Scand J Infect Dis. 2014;46(3):210–4.

    Article  CAS  PubMed  Google Scholar 

  21. Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev. 2004;17(4):770–82, table of contents.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Mansharamani NG, Garland R, Delaney D, Koziel H. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. Chest. 2000;118(3):704–11.

    Article  CAS  PubMed  Google Scholar 

  23. Cooley L, Dendle C, Wolf J, Teh BW, Chen SC, Boutlis C, et al. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014. Intern Med J. 2014;44(12b):1350–63.

    Article  CAS  PubMed  Google Scholar 

  24. Messiaen PE, Cuyx S, Dejagere T, van der Hilst JC. The role of CD4 cell count as discriminatory measure to guide chemoprophylaxis against Pneumocystis jirovecii pneumonia in human immunodeficiency virus-negative immunocompromised patients: a systematic review. Transpl Infect Dis. 2017;19(2)

    Google Scholar 

  25. Baulier G, Issa N, Gabriel F, Accoceberry I, Camou F, Duffau P. Guidelines for prophylaxis of Pneumocystis pneumonia cannot rely solely on CD4-cell count in autoimmune and inflammatory diseases. Clin Exp Rheumatol. 2018;36(3):490–3.

    PubMed  Google Scholar 

  26. Neofytos D, Hirzel C, Boely E, Lecompte T, Khanna N, Mueller NJ, et al. Pneumocystis jirovecii pneumonia in solid organ transplant recipients: a descriptive analysis for the Swiss transplant cohort. Transpl Infect Dis. 2018;20(6):e12984.

    Article  PubMed  CAS  Google Scholar 

  27. Iriart X, Bouar ML, Kamar N, Berry A. Pneumocystis pneumonia in solid-organ transplant recipients. J Fungi (Basel). 2015;1(3):293–331.

    Article  Google Scholar 

  28. Fishman JA, Gans H, Practice ASTIDCo. Pneumocystis jiroveci in Solid Organ transplantation – guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;e13587

    Google Scholar 

  29. Werbel WA, Ison MG, Angarone MP, Yang A, Stosor V. Lymphopenia is associated with late onset Pneumocystis jirovecii pneumonia in solid organ transplantation. Transpl Infect Dis. 2018;20(3):e12876.

    Article  CAS  PubMed  Google Scholar 

  30. Hosseini-Moghaddam SM, Shokoohi M, Singh G, Dufresne SF, Boucher A, Jevnikar A, et al. A multi-center case-control study of the effect of acute rejection and Cytomegalovirus Infection on Pneumocystis Pneumonia (PCP) in solid organ transplant recipients. Clin Infect Dis. 2018;

    Google Scholar 

  31. Faure E, Lionet A, Kipnis E, Noel C, Hazzan M. Risk factors for Pneumocystis pneumonia after the first 6 months following renal transplantation. Transpl Infect Dis. 2017;19(5)

    Google Scholar 

  32. Yu Q, Jia P, Su L, Zhao H, Que C. Outcomes and prognostic factors of non-HIV patients with Pneumocystis jirovecii pneumonia and pulmonary CMV co-infection: a retrospective cohort study. BMC Infect Dis. 2017;17(1):392.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  33. Korkmaz Ekren P, Toreyin ZN, Nahid P, Doskaya M, Caner A, Turgay N, et al. The association between Cytomegalovirus co-infection with Pneumocystis pneumonia and mortality in immunocompromised non-HIV patients. Clin Respir J. 2018;12(11):2590–7.

    Article  CAS  PubMed  Google Scholar 

  34. Park SY, Jung JH, Kwon H, Shin S, Kim YH, Chong YP, et al. Epidemiology and risk factors associated with Pneumocystis jirovecii pneumonia in kidney transplant recipients after 6-month trimethoprim-sulfamethoxazole prophylaxis: a case-control study. Transpl Infect Dis. 2020;e13245

    Google Scholar 

  35. Hosseini-Moghaddam SM, Krishnan RJ, Guo H, Kumar D. Cytomegalovirus infection and graft rejection as risk factors for pneumocystis pneumonia in solid organ transplant recipients: a systematic review and meta-analysis. Clin Transpl. 2018;32(8):e13339.

    Article  Google Scholar 

  36. Fishman JA. Pneumocystis jiroveci. Semin Respir Crit Care Med. 2020;41(1):141–57.

    Article  PubMed  Google Scholar 

  37. Schuster MG, Cleveland AA, Dubberke ER, Kauffman CA, Avery RK, Husain S, et al. Infections in hematopoietic cell transplant recipients: results from the organ transplant infection project, a multicenter, prospective, cohort study. Open Forum Infect Dis. 2017;4(2):ofx050.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Williams KM, Ahn KW, Chen M, Aljurf MD, Agwu AL, Chen AR, et al. The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysis. Bone Marrow Transplant. 2016;51(4):573–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Redjoul R, Robin C, Foulet F, Leclerc M, Beckerich F, Cabanne L, et al. Pneumocystis jirovecii pneumonia prophylaxis in allogeneic hematopoietic cell transplant recipients: can we always follow the guidelines? Bone Marrow Transplant. 2018;54:1082.

    Article  PubMed  CAS  Google Scholar 

  40. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143–238.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Maertens J, Cesaro S, Maschmeyer G, Einsele H, Donnelly JP, Alanio A, et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016;71(9):2397–404.

    Article  CAS  PubMed  Google Scholar 

  42. Chamilos G, Lionakis MS, Kontoyiannis DP. Call for action: invasive fungal infections associated with Ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways. Clin Infect Dis. 2018;66(1):140–8.

    Article  CAS  PubMed  Google Scholar 

  43. Dioverti MV, Abu Saleh OM, Tande AJ. Infectious complications in patients on treatment with Ruxolitinib: case report and review of the literature. Infect Dis (Lond). 2018;50(5):381–7.

    Article  CAS  Google Scholar 

  44. Jones JA, Robak T, Brown JR, Awan FT, Badoux X, Coutre S, et al. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematol. 2017;4(3):e114–e26.

    Article  PubMed  Google Scholar 

  45. Yiannakis EP, Boswell TC. Systematic review of outbreaks of Pneumocystis jirovecii pneumonia: evidence that P. jirovecii is a transmissible organism and the implications for healthcare infection control. J Hosp Infect. 2016;93(1):1–8.

    Article  CAS  PubMed  Google Scholar 

  46. Veronese G, Ammirati E, Moioli MC, Baldan R, Orcese CA, De Rezende G, et al. Single-center outbreak of Pneumocystis jirovecii pneumonia in heart transplant recipients. Transpl Infect Dis. 2018;20(3):e12880.

    Article  PubMed  Google Scholar 

  47. White PL, Price JS, Backx M. Therapy and management of Pneumocystis jirovecii infection. J Fungi (Basel). 2018;4(4)

    Google Scholar 

  48. Vasconcelles MJ, Bernardo MV, King C, Weller EA, Antin JH. Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. Biol Blood Marrow Transplant. 2000;6(1):35–43.

    Article  CAS  PubMed  Google Scholar 

  49. Branten AJ, Beckers PJ, Tiggeler RG, Hoitsma AJ. Pneumocystis carinii pneumonia in renal transplant recipients. Nephrol Dial Transplant. 1995;10(7):1194–7.

    Article  CAS  PubMed  Google Scholar 

  50. Olsen SL, Renlund DG, O’Connell JB, Taylor DO, Lassetter JE, Eastburn TE, et al. Prevention of Pneumocystis carinii pneumonia in cardiac transplant recipients by trimethoprim sulfamethoxazole. Transplantation. 1993;56(2):359–62.

    Article  CAS  PubMed  Google Scholar 

  51. Purdy BH, Philips DM, Summers RW. Desensitization for sulfasalazine skin rash. Ann Intern Med. 1984;100(4):512–4.

    Article  CAS  PubMed  Google Scholar 

  52. Leoung GS, Stanford JF, Giordano MF, Stein A, Torres RA, Giffen CA, et al. Trimethoprim-sulfamethoxazole (TMP-SMZ) dose escalation versus direct rechallenge for Pneumocystis Carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with previous adverse reaction to TMP-SMZ. J Infect Dis. 2001;184(8):992–7.

    Article  CAS  PubMed  Google Scholar 

  53. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007;82(9):1052–9.

    Article  CAS  PubMed  Google Scholar 

  54. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev. 2007;3:CD005590.

    Google Scholar 

  55. Souza JP, Boeckh M, Gooley TA, Flowers ME, Crawford SW. High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis. Clin Infect Dis. 1999;29(6):1467–71.

    Article  CAS  PubMed  Google Scholar 

  56. Urbancic KF, Pisasale D, Wight J, Trubiano JA. Dapsone safety in hematology patients: pathways to optimizing Pneumocystis jirovecii pneumonia prophylaxis in hematology malignancy and transplant recipients. Transpl Infect Dis. 2018;20(6):e12968.

    Article  PubMed  CAS  Google Scholar 

  57. Sangiolo D, Storer B, Nash R, Corey L, Davis C, Flowers M, et al. Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control study. Biol Blood Marrow Transplant. 2005;11(7):521–9.

    Article  CAS  PubMed  Google Scholar 

  58. Chan C, Montaner J, Lefebvre EA, Morey G, Dohn M, McIvor RA, et al. Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. J Infect Dis. 1999;180(2):369–76.

    Article  CAS  PubMed  Google Scholar 

  59. El-Sadr WM, Murphy RL, Yurik TM, Luskin-Hawk R, Cheung TW, Balfour HH Jr, et al. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. N Engl J Med. 1998;339(26):1889–95.

    Article  CAS  PubMed  Google Scholar 

  60. Beck-Sague C, Dooley SW, Hutton MD, Otten J, Breeden A, Crawford JT, et al. Hospital outbreak of multidrug-resistant Mycobacterium tuberculosis infections. Factors in transmission to staff and HIV-infected patients. JAMA. 1992;268(10):1280–6.

    Article  CAS  PubMed  Google Scholar 

  61. Hardy WD, Northfelt DW, Drake TA. Fatal, disseminated pneumocystosis in a patient with acquired immunodeficiency syndrome receiving prophylactic aerosolized pentamidine. Am J Med. 1989;87(3):329–31.

    Article  CAS  PubMed  Google Scholar 

  62. Mahon FX, Sadoun A, Benz-Lemoine E, Roblot-Casenave F, Guilhot F, Tanzer J. Possible prevention of Pneumocystis carinii pneumonia by pentamidine aerosol after bone marrow transplantation. Bone Marrow Transplant. 1991;8(1):64–5.

    CAS  PubMed  Google Scholar 

  63. Link H, Vohringer HF, Wingen F, Bragas B, Schwardt A, Ehninger G. Pentamidine aerosol for prophylaxis of Pneumocystis carinii pneumonia after BMT. Bone Marrow Transplant. 1993;11(5):403–6.

    CAS  PubMed  Google Scholar 

  64. Machado CM, Macedo MC, Medeiros RS, Massumoto C, Silva AC, Castelli JB, et al. Primary Pneumocystis carinii prophylaxis with aerosolized pentamidine after bone marrow transplantation. Acta Haematol. 1998;99(1):54–6.

    Article  CAS  PubMed  Google Scholar 

  65. Marras TK, Sanders K, Lipton JH, Messner HA, Conly J, Chan CK. Aerosolized pentamidine prophylaxis for Pneumocystis carinii pneumonia after allogeneic marrow transplantation. Transpl Infect Dis. 2002;4(2):66–74.

    Article  CAS  PubMed  Google Scholar 

  66. Schmidt JJ, Lueck C, Ziesing S, Stoll M, Haller H, Gottlieb J, et al. Clinical course, treatment and outcome of Pneumocystis pneumonia in immunocompromised adults: a retrospective analysis over 17 years. Crit Care. 2018;22(1):307.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Kanne JP, Yandow DR, Meyer CA. Pneumocystis jiroveci pneumonia: high-resolution CT findings in patients with and without HIV infection. AJR Am J Roentgenol. 2012;198(6):W555–61.

    Article  PubMed  Google Scholar 

  68. Ebner L, Walti LN, Rauch A, Furrer H, Cusini A, Meyer AM, et al. Clinical course, radiological manifestations, and outcome of Pneumocystis jirovecii pneumonia in HIV patients and renal transplant recipients. PLoS One. 2016;11(11):e0164320.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  69. Turner D, Schwarz Y, Yust I. Induced sputum for diagnosing Pneumocystis carinii pneumonia in HIV patients: new data, new issues. Eur Respir J. 2003;21(2):204–8.

    Article  CAS  PubMed  Google Scholar 

  70. Kovacs JA, Ng VL, Masur H, Leoung G, Hadley WK, Evans G, et al. Diagnosis of Pneumocystis carinii pneumonia: improved detection in sputum with use of monoclonal antibodies. N Engl J Med. 1988;318(10):589–93.

    Article  CAS  PubMed  Google Scholar 

  71. Alanio A, Hauser PM, Lagrou K, Melchers WJ, Helweg-Larsen J, Matos O, et al. ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016;71(9):2386–96.

    Article  CAS  PubMed  Google Scholar 

  72. Robert-Gangneux F, Belaz S, Revest M, Tattevin P, Jouneau S, Decaux O, et al. Diagnosis of Pneumocystis jirovecii pneumonia in immunocompromised patients by real-time PCR: a 4-year prospective study. J Clin Microbiol. 2014;52(9):3370–6.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Fan LC, Lu HW, Cheng KB, Li HP, Xu JF. Evaluation of PCR in bronchoalveolar lavage fluid for diagnosis of Pneumocystis jirovecii pneumonia: a bivariate meta-analysis and systematic review. PLoS One. 2013;8(9):e73099.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Bienvenu AL, Traore K, Plekhanova I, Bouchrik M, Bossard C, Picot S. Pneumocystis pneumonia suspected cases in 604 non-HIV and HIV patients. Int J Infect Dis. 2016;46:11–7.

    Article  PubMed  Google Scholar 

  75. Huh HJ, Lim KR, Ki CS, Huh K, Shim HJ, Song DJ, et al. Comparative evaluation between the RealStar Pneumocystis jirovecii PCR kit and the AmpliSens Pneumocystis jirovecii (carinii)-FRT PCR kit for detecting P. jirovecii in non-HIV immunocompromised patients. Ann Lab Med. 2019;39(2):176–82.

    Article  CAS  PubMed  Google Scholar 

  76. Botterel F, Cabaret O, Foulet F, Cordonnier C, Costa JM, Bretagne S. Clinical significance of quantifying Pneumocystis jirovecii DNA by using real-time PCR in bronchoalveolar lavage fluid from immunocompromised patients. J Clin Microbiol. 2012;50(2):227–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Montesinos I, Brancart F, Schepers K, Jacobs F, Denis O, Delforge ML. Comparison of 2 real-time PCR assays for diagnosis of Pneumocystis jirovecii pneumonia in human immunodeficiency virus (HIV) and non-HIV immunocompromised patients. Diagn Microbiol Infect Dis. 2015;82(2):143–7.

    Article  CAS  PubMed  Google Scholar 

  78. Morris A, Wei K, Afshar K, Huang L. Epidemiology and clinical significance of pneumocystis colonization. J Infect Dis. 2008;197(1):10–7.

    Article  CAS  PubMed  Google Scholar 

  79. Lee HY, Kang HS, Lee HY, Rhee CK, Lee SY, Kim SC, et al. Clinical significance of positive Pneumocystis jirovecii polymerase chain reaction in non-human immunodeficiency virus immunocompromised patients in a real practice. Korean J Intern Med. 2017;32(3):478–85.

    Article  PubMed  Google Scholar 

  80. Fauchier T, Hasseine L, Gari-Toussaint M, Casanova V, Marty PM, Pomares C. Detection of Pneumocystis jirovecii by quantitative PCR to differentiate colonization and pneumonia in immunocompromised HIV-positive and HIV-negative patients. J Clin Microbiol. 2016;54(6):1487–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55(4):611–22.

    Article  CAS  PubMed  Google Scholar 

  82. Held J, Koch MS, Reischl U, Danner T, Serr A. Serum (1 → 3)-beta-D-glucan measurement as an early indicator of Pneumocystis jirovecii pneumonia and evaluation of its prognostic value. Clin Microbiol Infect. 2011;17(4):595–602.

    Article  CAS  PubMed  Google Scholar 

  83. Wang D, Hu Y, Li T, Rong HM, Tong ZH. Diagnosis of Pneumocystis jirovecii pneumonia with serum cell-free DNA in non-HIV-infected immunocompromised patients. Oncotarget. 2017;8(42):71946–53.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Yoon C, Subramanian A, Chi A, Crothers K, Meshnick SR, Taylor SM, et al. Dihydropteroate synthase mutations in Pneumocystis pneumonia: impact of applying different definitions of prophylaxis, mortality endpoints and mutant in a single cohort. Med Mycol. 2013;51(6):568–75.

    Article  CAS  PubMed  Google Scholar 

  85. Montesinos I, Delforge ML, Ajjaham F, Brancart F, Hites M, Jacobs F, et al. Evaluation of a new commercial real-time PCR assay for diagnosis of Pneumocystis jirovecii pneumonia and identification of dihydropteroate synthase (DHPS) mutations. Diagn Microbiol Infect Dis. 2017;87(1):32–6.

    Article  CAS  PubMed  Google Scholar 

  86. Li WJ, Guo YL, Liu TJ, Wang K, Kong JL. Diagnosis of pneumocystis pneumonia using serum (1-3)-beta-D-Glucan: a bivariate meta-analysis and systematic review. J Thorac Dis. 2015;7(12):2214–25.

    PubMed  PubMed Central  Google Scholar 

  87. Onishi A, Sugiyama D, Kogata Y, Saegusa J, Sugimoto T, Kawano S, et al. Diagnostic accuracy of serum 1,3-beta-D-glucan for pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis. J Clin Microbiol. 2012;50(1):7–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Karageorgopoulos DE, Qu JM, Korbila IP, Zhu YG, Vasileiou VA, Falagas ME. Accuracy of beta-D-glucan for the diagnosis of Pneumocystis jirovecii pneumonia: a meta-analysis. Clin Microbiol Infect. 2013;19(1):39–49.

    Article  CAS  PubMed  Google Scholar 

  89. Nakamura H, Tateyama M, Tasato D, Haranaga S, Yara S, Higa F, et al. Clinical utility of serum beta-D-glucan and KL-6 levels in Pneumocystis jirovecii pneumonia. Intern Med. 2009;48(4):195–202.

    Article  PubMed  Google Scholar 

  90. Lahmer T, da Costa CP, Held J, Rasch S, Ehmer U, Schmid RM, et al. Usefulness of 1,3 Beta-D-glucan detection in non-HIV immunocompromised mechanical ventilated critically ill patients with ARDS and suspected Pneumocystis jirovecii pneumonia. Mycopathologia. 2017;182(7–8):701–8.

    Article  CAS  PubMed  Google Scholar 

  91. Damiani C, Le Gal S, Da Costa C, Virmaux M, Nevez G, Totet A. Combined quantification of pulmonary Pneumocystis jirovecii DNA and serum (1→3)-beta-D-glucan for differential diagnosis of pneumocystis pneumonia and Pneumocystis colonization. J Clin Microbiol. 2013;51(10):3380–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Matsumura Y, Shindo Y, Iinuma Y, Yamamoto M, Shirano M, Matsushima A, et al. Clinical characteristics of Pneumocystis pneumonia in non-HIV patients and prognostic factors including microbiological genotypes. BMC Infect Dis. 2011;11:76.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Held J, Wagner D. Beta-d-glucan kinetics for the assessment of treatment response in Pneumocystis jirovecii pneumonia. Clin Microbiol Infect. 2011;17(7):1118–22.

    Article  CAS  PubMed  Google Scholar 

  94. Maschmeyer G, Helweg-Larsen J, Pagano L, Robin C, Cordonnier C, Schellongowski P, et al. ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients. J Antimicrob Chemother. 2016;71(9):2405–13.

    Article  CAS  PubMed  Google Scholar 

  95. Kosaka M, Ushiki A, Ikuyama Y, Hirai K, Matsuo A, Hachiya T, et al. A Four-center retrospective study of the efficacy and toxicity of low-dose trimethoprim-sulfamethoxazole for the treatment of pneumocystis pneumonia in patients without HIV infection. Antimicrob Agents Chemother. 2017;61(12):e01173.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Ponce CA, Chabe M, George C, Cardenas A, Duran L, Guerrero J, et al. High prevalence of Pneumocystis jirovecii Dihydropteroate synthase gene mutations in patients with a first episode of pneumocystis pneumonia in Santiago, Chile, and clinical response to trimethoprim-sulfamethoxazole therapy. Antimicrob Agents Chemother. 2017;61(2):e01290.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Wieruszewski PM, Barreto JN, Frazee E, Daniels CE, Tosh PK, Dierkhising RA, et al. Early corticosteroids for Pneumocystis pneumonia in adults without HIV are not associated with better outcome. Chest. 2018;154(3):636–44.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Shmuel Shoham

  2. Infectious Diseases, Johns Hopkins University, Baltimore, MD, USA

    M. Veronica Dioverti Prono

Authors
  1. Shmuel Shoham
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Veronica Dioverti Prono
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shmuel Shoham .

Editor information

Editors and Affiliations

  1. Immunocompromised Host Service Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, FL, USA

    Michele I. Morris

  2. Transplant and Immunocompromised Host Infectious Diseases, Infectious Diseases Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    Camille Nelson Kotton

  3. Division of Infectious Diseases, Duke University School of Medicine, Durham, NC, USA

    Cameron R. Wolfe

Section Editor information

  1. Duke University, Durham, NC, USA

    Cameron R. Wolfe

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Shoham, S., Dioverti Prono, M.V. (2021). Pneumocystis jiroveci in Transplant: Recognizing Risk, Understanding Prevention, and Implementing Treatment. In: Morris, M.I., Kotton, C.N., Wolfe, C.R. (eds) Emerging Transplant Infections. Springer, Cham. https://doi.org/10.1007/978-3-030-25869-6_48

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-25869-6_48

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-25868-9

  • Online ISBN: 978-3-030-25869-6

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation